Baishideng publishing group inc

REFERENCES

1 Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-1318 [PMID: 17389705]

2 Mindikoglu AL, Weir MR. Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. Am J Nephrol 2013; 38: 345-354 [PMID: 24107793 DOI: 10.1159/000355540]

3 Liangpunsakul S, Agarwal R. Renal failure in cirrhosis: is it time to change the diagnosis and classification? Am J Nephrol 2013; 38: 342-344 [PMID: 24107717 DOI: 10.1159/000355570]

4 Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362: 1819-1827 [PMID: 14654322 DOI: 10.1016/S0140-6736(03)14903-3]

5 Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-1290 [PMID: 19776409 DOI: 10.1056/NEJMra0809139]

6 Pillebout E. Hepatorenal syndrome. Nephrol Ther 2014; 10: 61-68 [PMID: 24388293 DOI: 10.1016/j.nephro.2013.11.005]

7 Wadei HM. Hepatorenal syndrome: a critical update. Semin Respir Crit Care Med 2012; 33: 55-69 [PMID: 22447261 DOI: 10.1055/s-0032-1301735]

8 Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-433 [PMID: 15723320 DOI: 10.1002/hep.20632]

9 Francés R, González-Navajas JM, Zapater P, Muñoz C, Caño R, Pascual S, Santana F, Márquez D, Pérez-Mateo M, Such J. Translocation of bacterial DNA from Gram-positive microorganisms is associated with a species-specific inflammatory response in serum and ascitic fluid of patients with cirrhosis. Clin Exp Immunol 2007; 150: 230-237 [PMID: 17822441 DOI: 10.1111/j.1365-2249.2007.03494.x]

10 Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA, Sikaroodi M, Gillevet PM. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012; 303: G675-G685 [PMID: 22821944 DOI: 10.1152/ajpgi.00152.2012]

11 Oliver JA, Verna EC. Afferent mechanisms of sodium retention in cirrhosis and hepatorenal syndrome. Kidney Int 2010; 77: 669-680 [PMID: 20147888 DOI: 10.1038/ki.2010.4]

12 Fagundes C, Ginès P. Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis. Am J Kidney Dis 2012; 59: 874-885 [PMID: 22480795 DOI: 10.1053/j.ajkd.2011.12.032]

13 Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int 2014; 8: 308-315 [PMID: 25221635 DOI: 10.1007/s12072-014-9531]

14 Mocarzel L, Lanzieri P, Nascimento J, Peixoto C, Ribeiro M, Mesquita E. Hepatorenal syndrome with cirrhotic cardiomyopathy: case report and literature review. Case Reports Hepatol 2015; 2015: 573513 [PMID: 25874140 DOI: 10.1155/2015/573513]

15 Fede G, D’Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, Morabito A, Burroughs AK. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012; 56: 810-818 [PMID: 22173162 DOI: 10.1016/j.jhep.2011.10.016]

16 Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648 [PMID: 11113085 DOI: 10.1053/gast.2000.20189]

17 Planas R, Montoliu S, Ballesté B, Rivera M, Miquel M, Masnou H, Galeras JA, Giménez MD, Santos J, Cirera I, Morillas RM, Coll S, Solà R. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006; 4: 1385-1394 [PMID: 17081806 DOI: 10.1016/j.cgh.2006.08.007]

18 Wong LP, Blackley MP, Andreoni KA, Chin H, Falk RJ, Klemmer PJ. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int 2005; 68: 362-370 [PMID: 15954928 DOI: 10.1111/j.1523-1755.2005.00408.x]

19 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417 [PMID: 20633946 DOI: 10.1016/j.jhep.2010.05.004]

20 Hkecer R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956; 271: 1121-1125 [PMID: 13377688 DOI: 10.1016/S0140-6736(56)90149-0]

21 Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease. N Engl J Med 1969; 280: 1367-1371 [PMID: 4890476 DOI: 10.1056/NEJM196906192802501]

22 Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Schölmerich J. Definition and diagno­stic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176 [PMID: 8550036 DOI: 10.1002/hep.510230122]

23 Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current manage­ment. J Hepatol 2003; 38 Suppl 1: S69-S89 [PMID: 12591187 DOI: 10.1016/S0168-8278(03)00007-2]

24 Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, Salinas F, Donà S, Fagiuoli S, Sticca A, Zanus G, Cillo U, Frasson I, Destro C, Gatta A. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007; 45: 223-229 [PMID: 17187409 DOI: 10.1002/hep.21443]

25 Moore K. Acute kidney injury in cirrhosis: a changing spectrum. Hepatology 2013; 57: 435-437 [PMID: 22886711 DOI: 10.1002/hep.26003]

26 Nadim MK, Kellum JA, Davenport A, Wong F, Davis C, Pannu N, Tolwani A, Bellomo R, Genyk YS. Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2012; 16: R23 [PMID: 22322077 DOI: 10.1186/cc11188]

27 Fagundes C, Barreto R, Guevara M, Garcia E, Solà E, Rodríguez E, Graupera I, Ariza X, Pereira G, Alfaro I, Cárdenas A, Fernández J, Poch E, Ginès P. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol 2013; 59: 474-481 [PMID: 23669284 DOI: 10.1016/j.jhep.2013.04.036]

28 Piano S, Rosi S, Maresio G, Fasolato S, Cavallin M, Romano A, Morando F, Gola E, Frigo AC, Gatta A, Angeli P. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol 2013; 59: 482-489 [PMID: 23665185 DOI: 10.1016/j.jhep.2013.03.039]

29 Arroyo V. Acute kidney injury (AKI) in cirrhosis: should we change current definition and diagnostic criteria of renal failure in cirrhosis? J Hepatol 2013; 59: 415-417 [PMID: 23727236 DOI: 10.1016/j.jhep.2013.05.035]

30 Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, Angeli P, Moreau R, Davenport A, Jalan R, Ronco C, Genyk Y, Arroyo V. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60: 702-709 [PMID: 21325171 DOI: 10.1136/gut.2010.23613]

31 Seo YS, Jung ES, An H, Kim JH, Jung YK, Kim JH, Yim HJ, Yeon JE, Byun KS, Kim CD, Ryu HS, Um SH. Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels. Liver Int 2009; 29: 1521-1527 [PMID: 19725889 DOI: 10.1111/j.1478-3231]

32 Sharawey MA, Shawky EM, Ali LH, Mohammed AA, Hassan HA, Fouad YM. Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis. Hepatol Int 2011; 5: 927-933 [PMID: 21484118 DOI: 10.1007/s12072-011-9266-y]

33 Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015; 62: 968-974 [PMID: 25638527 DOI: 10.1016/j.jhep.2014]

34 Møller S, Krag A, Bendtsen F. Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. Liver Int 2014; 34: 1153-1163 [PMID: 24673771 DOI: 10.1111/liv.12549]

35 Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 48: 2064-2077 [PMID: 19003880 DOI: 10.1002/hep.22605]

36 Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, Ansari N, Coca SG, Garcia-Tsao G, Parikh CR. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2014; 60: 622-632 [PMID: 24375576 DOI: 10.1002/hep.26980]

37 Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, Adkins SH, Sise ME, Oliver JA, Radhakrishnan J, Barasch JM, Nickolas TL. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012; 57: 2362-2370 [PMID: 22562534 DOI: 10.1007/s10620-012-2180-x]

38 Fagundes C, Pépin MN, Guevara M, Barreto R, Casals G, Solà E, Pereira G, Rodríguez E, Garcia E, Prado V, Poch E, Jiménez W, Fernández J, Arroyo V, Ginès P. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol 2012; 57: 267-273 [PMID: 22521351 DOI: 10.1016/j.jhep.2012.03.015]

39 Barreto R, Elia C, Solà E, Moreira R, Ariza X, Rodríguez E, Graupera I, Alfaro I, Morales-Ruiz M, Poch E, Guevara M, Fernández J, Jiménez W, Arroyo V, Ginès P. Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. J Hepatol 2014; 61: 35-42 [PMID: 24613364 DOI: 10.1016/j.jhep.2014.02.023]

40 Fabrizi F, Aghemo A, Messa P. Hepatorenal syndrome and novel advances in its management. Kidney Blood Press Res 2013; 37: 588-601 [PMID: 24356549 DOI: 10.1159/000355739]

41 Davenport A, Ahmad J, Al-Khafaji A, Kellum JA, Genyk YS, Nadim MK. Medical management of hepatorenal syndrome. Nephrol Dial Transplant 2012; 27: 34-41 [PMID: 22287700 DOI: 10.1093/ndt/gfr736]

42 Ginès A, Fernández-Esparrach G, Monescillo A, Vila C, Domènech E, Abecasis R, Angeli P, Ruiz-Del-Arbol L, Planas R, Solà R, Ginès P, Terg R, Inglada L, Vaqué P, Salerno F, Vargas V, Clemente G, Quer JC, Jiménez W, Arroyo V, Rodés J. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-1010 [PMID: 8831595 DOI: 10.1016/S0016-5085(96)70068-9]

43 García-Compean D, Blanc P, Larrey D, Daures JP, Hirtz J, Mendoza E, Maldonado H, Michel H. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol 2002; 1: 29-35 [PMID: 15114293]

44 Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Ginès P, Arroyo V. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824 [PMID: 17854593 DOI: 10.1053/j.gastro.2007.06.065]

45 Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P, Rodés J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-409 [PMID: 10432325 DOI: 10.1056/NEJM199908053410603]

46 Fernández J, Escorsell A, Zabalza M, Felipe V, Navasa M, Mas A, Lacy AM, Ginès P, Arroyo V. Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology 2006; 44: 1288-1295 [PMID: 17058239 DOI: 10.1002/hep.21352]

47 Barbano B, Sardo L, Gigante A, Gasperini ML, Liberatori M, Giraldi GD, Lacanna A, Amoroso A, Cianci R. Pathophysiology, diagnosis and clinical management of hepatorenal syndrome: from classic to new drugs. Curr Vasc Pharmacol 2014; 12: 125-135 [PMID: 24678726 DOI: 10.2174/157016111201140327163930]

48 Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47: 499-505 [PMID: 17560680 DOI: 10.1016/j.jhep.2007.04.010]

49 Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-1697 [PMID: 10347109 DOI: 10.1002/hep.510290629]

50 Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P. Terlipre­ssin and albumin vs albumin in patients with cirrhosis and hepato­renal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-1359 [PMID: 18471512 DOI: 10.1053/j.gastro.­2008.02.024]

51 Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-1368 [PMID: 18471513 DOI: 10.1053/j.gastro.2008.02.014]

52 Angeli P. Review article: prognosis of hepatorenal syndrome--has it changed with current practice? Aliment Pharmacol Ther 2004; 20 Suppl 3: 44-6; discussion 47-8 [PMID: 15335400 DOI: 10.1111/j.1365-2036.2004.02113.x]

53 Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576-584 [PMID: 19885875 DOI: 10.1002/hep.23286]

54 Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 2006; 24: 935-944 [PMID: 16948805 DOI: 10.1111/j.1365-2036.2006.03086.x]

55 Sugumaran A, Lougher E, Czajkowski M, Yeoman A. Reduction of serum sodium (Na) in patients treated with terlipressin for variceal bleeding (VB) and hepatorenal syndrome (HRS). Gut 2014; 63: A87-A88 [DOI: 10.1136/gutjnl-2014-307263.184]

56 Fabrizi F, Dixit V, Messa P, Martin P. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials. Int J Artif Organs 2009; 32: 133-140 [PMID: 19440988]

57 Duvoux C, Zanditenas D, Hézode C, Chauvat A, Monin JL, Roudot-Thoraval F, Mallat A, Dhumeaux D. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002; 36: 374-380 [PMID: 12143045 DOI: 10.1053/jhep.2002.34343]

58 Wadei HM, Gonwa TA. Hepatorenal syndrome in the intensive care unit. J Intensive Care Med 2013; 28: 79-92 [PMID: 21859679 DOI: 10.1177/0885066611408692]

59 Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, Sharma N, Bhalla A, Chawla YK, Singh V. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int 2013; 33: 1187-1193 [PMID: 23601499 DOI: 10.1111/liv.12179]

60 Prabhu MV, Sukanya B, Santosh Pai BH, Reddy S. The hepatorenal syndrome - a review. G Ital Nefrol 2014; 31: [PMID: 25030015]

61 Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007; 52: 742-748 [PMID: 17235705 DOI: 10.1007/s10620-006-9312-0]

62 Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64 [PMID: 15239086 DOI: 10.1002/hep.20262]

63 Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, Kramer HJ, Spengler U, Schild H, Sauerbruch T. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288-295 [PMID: 10896924 DOI: 10.1136/gut.47.2.288]

64 Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, Garcia-Pagan JC, Bosch J, Arroyo V, Rodés J. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416-422 [PMID: 9696006 DOI: 10.1002/hep.510280219]

65 Pipili C, Cholongitas E. Renal dysfunction in patients with cirrhosis: Where do we stand? World J Gastrointest Pharmacol Ther 2014; 5: 156-168 [PMID: 25133044 DOI: 10.4292/wjgpt.v5.i3.156]

66 Keller F, Heinze H, Jochimsen F, Passfall J, Schuppan D, Büttner P. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail 1995; 17: 135-146 [PMID: 7644764 DOI: 10.3109/08860229509026250]

67 Wilkinson SP, Weston MJ, Parsons V, Williams R. Dialysis in the treatment of renal failure in patients with liver disease. Clin Nephrol 1977; 8: 287-292 [PMID: 884909]

68 Davenport A. Renal replacement therapy in the patient with acute brain injury. Am J Kidney Dis 2001; 37: 457-466 [PMID: 11228168 DOI: 10.1053/ajkd.2001.22068]

69 Witzke O, Baumann M, Patschan D, Patschan S, Mitchell A, Treichel U, Gerken G, Philipp T, Kribben A. Which patients benefit from hemodialysis therapy in hepatorenal syndrome? J Gastroenterol Hepatol 2004; 19: 1369-1373 [PMID: 15610310 DOI: 10.1111/j.1440-1746.2004.03471.x]

70 Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. Renal replacement therapy and orthotopic liver transplantation: the role of continuous veno-venous hemodialysis. Transplantation 2001; 71: 1424-1428 [PMID: 11391230 DOI: 10.1097/00007890-200105270-00012]

71 Mackelaite L, Alsauskas ZC, Ranganna K. Renal failure in patients with cirrhosis. Med Clin North Am 2009; 93: 855-869, viii [PMID: 19577118 DOI: 10.1016/j.mcna.2009.03.003]

72 Patel S, Wendon J. Regional citrate anticoagulation in patients with liver failure--time for a rethink? Crit Care 2012; 16: 153 [PMID: 22985662 DOI: 10.1186/cc11492]

73 Pipili C, Polydorou A, Pantelias K, Korfiatis P, Nikolakopoulos F, Grapsa E. Improvement of hepatic encephalopathy by application of peritoneal dialysis in a patient with non-end-stage renal disease. Perit Dial Int 2013; 33: 213-216 [PMID: 23478376 DOI: 10.3747/pdi.2011.00271]

74 Liu KD, Himmelfarb J, Paganini E, Ikizler TA, Soroko SH, Mehta RL, Chertow GM. Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 2006; 1: 915-919 [PMID: 17699307 DOI: 10.2215/CJN.01430406]

75 Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, Lauchart W, Peszynski P, Freytag J, Hickstein H, Loock J, Löhr JM, Liebe S, Emmrich J, Korten G, Schmidt R. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-286 [PMID: 10827226 DOI: 10.1053/lv.2000.6355]

76 Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R, Nöldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12 Suppl 17: S75-S82 [PMID: 11251037]

77 Bañares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, Saliba F, Sauerbruch T, Klammt S, Ockenga J, Pares A, Wendon J, Brünnler T, Kramer L, Mathurin P, de la Mata M, Gasbarrini A, Müllhaupt B, Wilmer A, Laleman W, Eefsen M, Sen S, Zipprich A, Tenorio T, Pavesi M, Schmidt HH, Mitzner S, Williams R, Arroyo V. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013; 57: 1153-1162 [PMID: 23213075 DOI: 10.1002/hep.26185]

78 Donati G, La Manna G, Cianciolo G, Grandinetti V, Carretta E, Cappuccilli M, Panicali L, Iorio M, Piscaglia F, Bolondi L, Colì L, Stefoni S. Extracorporeal detoxification for hepatic failure using molecular adsorbent recirculating system: depurative efficiency and clinical results in a long-term follow-up. Artif Organs 2014; 38: 125-134 [PMID: 23834711 DOI: 10.1111/aor.12106]

79 Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, Sarrazin C, Hoste E, Van Vlierberghe H, Escorsell A, Hafer C, Schreiner O, Galle PR, Mancini E, Caraceni P, Karvellas CJ, Salmhofer H, Knotek M, Ginès P, Kozik-Jaromin J, Rifai K. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012; 142: 782-789.e3 [PMID: 22248661 DOI: 10.1053/j.gastro.2011.12.056]

80 Marik PE, Gayowski T, Starzl TE. The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med 2005; 33: 1254-1259 [PMID: 15942340 DOI: 10.1097/01.CCM.0000164541.12106.57]

81 Navasa M, Feu F, García-Pagán JC, Jiménez W, Llach J, Rimola A, Bosch J, Rodés J. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology 1993; 17: 355-360 [PMID: 8444409 DOI: 10.1002/hep.1840170302]

82 Piscaglia F, Zironi G, Gaiani S, Mazziotti A, Cavallari A, Gramantieri L, Valgimigli M, Bolondi L. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology 1999; 30: 58-64 [PMID: 10385639 DOI: 10.1002/hep.510300112]

83 Angeli P, Gines P. Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice. J Hepatol 2012; 57: 1135-1140 [PMID: 22749942 DOI: 10.1016/j.jhep.2012.06.024]

84 Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934-1939 [PMID: 11773892 DOI: 10.1097/00007890-200112270-00012]

85 Lee JP, Heo NJ, Joo KW, Yi NJ, Suh KS, Moon KC, Kim SG, Kim YS. Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function. Nephrol Dial Transplant 2010; 25: 2772-2785 [PMID: 20207711 DOI: 10.1093/ndt/gfq093]

86 Ruiz R, Barri YM, Jennings LW, Chinnakotla S, Goldstein RM, Levy MF, McKenna GJ, Randall HB, Sanchez EQ, Klintmalm GB. Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transpl 2007; 13: 838-843 [PMID: 17539003 DOI: 10.1002/lt.21149]

87 Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 2006; 21: 478-482 [PMID: 16249201 DOI: 10.1093/ndt/gfi212]

88 Gerbes AL, Gülberg V, Waggershauser T, Holl J, Reiser M. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 1998; 28: 683-688 [PMID: 9731559 DOI: 10.1002/hep.510280313]

89 Restuccia T, Ortega R, Guevara M, Ginès P, Alessandria C, Ozdogan O, Navasa M, Rimola A, Garcia-Valdecasas JC, Arroyo V, Rodés J. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004; 40: 140-146 [PMID: 14672625 DOI: 10.1016/j.jhep.2003.09.019]

90 Guevara M, Arroyo V. Hepatorenal syndrome. Expert Opin Pharma­cother 2011; 12: 1405-1417 [PMID: 21480763 DOI: 10.1517/14656566]
Figure Legends